Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
About this item
Full title
Author / Creator
Publisher
Turkey: AVES Yayincilik A.S
Journal title
Language
English
Formats
Publication information
Publisher
Turkey: AVES Yayincilik A.S
Subjects
More information
Scope and Contents
Contents
Rituximab (RTX) is approved for remission induction and maintenance of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). Observational studies demonstrate decline in immunoglobulin (IgG) in AAV post-RTX. The time course for the onset of hypogammaglobulinemia (Hypo-IgG) post-RTX is unknown. This is a key determinant in decidi...
Alternative Titles
Full title
Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b6a5fb1a923a4d458b4a732e30b650f5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b6a5fb1a923a4d458b4a732e30b650f5
Other Identifiers
ISSN
2147-9720
E-ISSN
2148-4279
DOI
10.5152/eujrheum.2022.20258
